HURA · TuHURA Biosciences, Inc./NV
Market Cap
$129.37M
Shares
63.73M
HURA metrics
49 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$2.09
Market cap
$129.37M
Price action
19 metricsPrice change (1W)
-0.5%
Price change (30D)
-5.1%
Price change (3M)
-6.9%
Price change (6M)
+31.0%
Price change (YTD)
+168.2%
Price change (1Y)
-24.8%
Trailing year
Price change (5Y)
—
52-week high
$3.15
52-week low
$0.44
Change from 52-week high
-35.6%
Change from 52-week low
+361.4%
Annualized volatility
129.8%
Beta
3.1
RSI (14D)
43.2
Price vs SMA 50
-9.4%
Price vs SMA 200
+11.8%
Avg volume (3M)
431,048
Relative volume
0.4
Average dollar volume
$976,517
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
63.73M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
7.0
reciprocal yield 14.3%
FCF yield
-23.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-24.4%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$11,516
Net income (TTM)
−$31.57M
Trailing 12 months
Diluted EPS (TTM)
$-0.54
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+43.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-170.7%
Return on assets
-99.5%
Debt / equity
—
Current ratio
0.2
EBITDA (TTM)
—
Free cash flow (TTM)
−$29.90M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$995,977
Total assets
$31.75M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$29.69M
Capital expenditures (TTM)
$213,674
R&D (TTM)
$22.88M
SG&A (TTM)
—
Stock compensation (TTM)
$8.53M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
90
13F filer change QoQ
0
Institutional ownership
14.1%
Short interest
3 metricsShort interest
9.9%
Latest settlement · 21.0 days to cover
Days to cover
21.0d
Short-squeeze score
68 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1498382
CUSIP
898920103
13F (30d)
75 filings
74 filers
Visit website
Investor relations